Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

被引：7

作者：

Otten, Marieke H. ^{[1
]}

Prince, Femke H. M. ^{[1
]}

Twilt, Marinka ^{[2
]}

van Rossum, Marion A. J. ^{[3
]}

Armbrust, Wineke ^{[4
]}

Hoppenreijs, Esther P. A. H. ^{[5
]}

Kamphuis, Sylvia ^{[1
]}

Koopman-Keemink, Yvonne ^{[6
]}

Wulffraat, Nico M. ^{[7
]}

Gorter, Simone L. ^{[8
]}

ten Cate, Rebecca ^{[2
]}

van Suijlekom-Smit, Lisette W. A. ^{[1
]}

机构：

[1] Erasmus MC, Sophia Childrens Hosp, Dept Paediat, NL-3000 CB Rotterdam, Netherlands

[2] Leiden Univ, Med Ctr, Dept Paediat, Leiden, Netherlands

[3] Emma Childrens Hosp, Acad Med Ctr, Jan van Breemen Inst, Dept Paediat, Amsterdam, Netherlands

[4] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Paediat, NL-9713 AV Groningen, Netherlands

[5] Radboud Univ Nijmegen, Med Ctr, Dept Paediat, NL-6525 ED Nijmegen, Netherlands

[6] Hagaziekenhuis Juliana Childrens Hosp, Dept Paediat, The Hague, Netherlands

[7] Utrecht MC Wilhelmina Childrens Hosp, Dept Paediat, Utrecht, Netherlands

[8] Univ Limburg, Acad Hosp Maastricht, Dept Internal Med, Rheumatol Subdiv, Maastricht, Netherlands

来源：

JOURNAL OF RHEUMATOLOGY | 2010年 / 37卷 / 03期

关键词：

JUVENILE IDIOPATHIC ARTHRITIS; ANTIRHEUMATIC AGENTS; TUMOR NECROSIS FACTOR-alpha; DRUG ADMINISTRATION SCHEDULE; TREATMENT OUTCOME; ARTHRITIS; RHEUMATOID-ARTHRITIS; EFFICACY; CHILDREN; THERAPY; SAFETY;

D O I：

10.3899/jrheum.090550

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To evaluate response in patients with juvenile idiopathic arthritis (JIA) who failed to meet response criteria after 3 months of etanercept treatment. Methods. This was a prospective ongoing Multicenter observational study of all Dutch patients with JIA using etanercept. Response according to American College of Rheumatology Pediatric 30 criteria was assessed at study start and at 3 and 15 months. Results. In total we studied 179 patients of median age 5.8 years at disease onset; 70% were female. Thirty-four patients did not respond after 3 months, of which 20 continued etanercept and 11 achieved response thereafter. Conclusion. The delayed clinically relevant response in a substantial proportion of patients who initially did not respond justifies the consideration of continuing therapy to at least 6 months. (First Release Jan 15 2010; J Rheumatol 20 10;37:665-7 doi: 10.3899/jrheum.090550)

引用

页码：665 / 667

页数：3